Phase 1 N=11 Treatment of Language and Memory in Patients With Alzheimer's Disease
Alzheimer Disease
Primary: Number of Successful Memory Tasks Completed Over Study Period. — 5; 0 memory tasks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=80 Losartan 100 mg Tablets in Healthy Subjects Under Fasting Conditions
Healthy
Primary: Cmax of Losartan (Maximum Observed Concentration of Drug Substance in Plasma) — 637.01; 582.39 ng/mL
Phase 1 N=80 Losartan 100 mg Tablet in Healthy Subjects Under Non-Fasting Conditions
Healthy
Primary: Cmax of Losartan (Maximum Observed Concentration of Drug Substance in Plasma) — 407.66; 360.82 ng/mL
Phase 1 N=77 Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)
Hypertension
Primary: Area Under the Curve (AUC(0 to Infinity)) of Losartan — 1018.1; 1024.9 ng*hr/mL
Phase 1 N=13 The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)
Hypertension
Primary: Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg — -24.9; -1.8 Percent…
Phase 1 N=47 A Study to Evaluate Methodologies for Measuring Swelling of the Leg and Ankle (MK-0000-106)(COMPLETED)
Hypertension
Primary: Change From Baseline in Segmental Bioimpedance Measurements at 10 Kilohertz (KHz) at Week 2 — -7.9; 3.8 Ohms — p=0.001
Phase 1 N=14 A Prospective Study of a New Device for Monitoring Cerebral Oxygenation on Healthy Volunteers
Cerebral Ischemia
Primary: Harm to Skin From Attachment of Sensor to Forehead: Cuts, Bruising, Rash or Allergic Reactions to Adhesive. — 0; 14 Participants
Phase 1 N=31 Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
Kidney Failure, Chronic
Primary: Net Phosphorous Absorption — 156.03; 221.78; 281.68 mg — p=<0.001
Phase 1 N=42 A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)
Chemotherapy-Induced Nausea and Vomiting
Primary: Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg — 34589; 39053; 37375; 37795…
Phase 1 N=13 Induced Sputum Study (0000-065)
Asthma
Primary: Hour 24 Fold Change From Period Baseline in Interleukin-5 (IL-5) Protein Concentration (pg/mL) — 2.57; 0.87 pg/mL — p=0.011
Phase 1 N=9 A Study To Assess The Effect Of Linezolid On QTc Interval
Bacterial Infections
Primary: Cohort 1: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 1; 3; 2; 0 participants
Phase 1 N=45 Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)
Chemotherapy-Induced Nausea and Vomiting
Primary: Plasma Area Under The Concentration Versus Time Curve (AUC(0-infinity)) For Ondansetron — 257.8; 262.6 ng*hr/mL
Phase 1 N=10 Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
Neoplasms, Colorectal
Primary: Overall Response in Phase II — 2 participants
Phase 1 N=9 Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg
Lupus Nephritis
Primary: Short-term Period: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, Discontinuations and Infusional AEs — 0; 0; 0; 0 Participants
Phase 1 N=16 Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Methotrexate Maximum Plasma Concentration — 215; 177 ng/mL